[p53 status and response to chemotherapy].
Numerous studies deal with "p53 status" in patients' tumors (mutated/wild gene status, protein level and functionality) to predict chemotherapy efficacy. Analyses of various cancers, especially breast cancers, lead to controversy that is apparent due to heterogeneity of their design. Recent data from literature lead now to consider i) the nature of chemotherapeutic agents and the regimen, ii) the cancer tissue type, and iii) the histological response of the primary. Molecular actors of senescence, cytostasis and apoptosis, which are responsible of cytotoxic response of cancer cells, are currently under elucidation.
Bénard
Jean
J
Unité de génétique tumorale, Service de génétique, Département de biologie clinique, Institut Gustave-Roussy, 94800 Villejuif, France.
Ahomadégbé
Jean-Charles
JC
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016158:Genes, p53; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*
D000970:Antineoplastic Agents